UNSPSC 51332807: Chlorpromazine

This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C17H19ClN2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U42B7VYA4P, chemically known as 10h-phenothiazine-10-propanamine, 2-chloro-n,n-dimethyl-, radical ion(1+) but generally known as chlorpromazine, which bears US NIH Compound Identifier 2726. European Medicines Agency schedules Chlorpromazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06208MIG.

UNSPSC 51332807 Chlorpromazine is a Commodity code that nominally covers a single pharmaceutical compound, but recent state and local activity under this code shows minimal direct alignment. The recent opportunities posted under this code actually solicit naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs and pharmacy benefit management (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance). The issuing bodies span county health departments, state HHS agencies, and cooperative procurement consortia serving multiple state and local jurisdictions. None of these solicitations specifically targets chlorpromazine or antipsychotic medications; the code assignment appears to reflect a miscategorization or a broader pharmaceutical procurement tagging convention rather than targeted buying of this specific compound.

Activity appears across Florida, Texas, and the Minnesota-led MMCAP consortium (which extends to Oregon and other participating states). Seminole County issued an IFB on June 30, 2026 for naloxone and safe drug deactivation systems with a response deadline of July 26, 2023 — a notice showing internal date inconsistencies. Texas HHS posted an RFI on April 3, 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs. MMCAP issued an RFP on January 20, 2026 (questions due February 18, 2026; proposals due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with contract effectiveness set for July 1, 2026. The code shows little relevant recent activity directly targeting chlorpromazine; firms should verify whether this code applies to their target product or whether procurement under this code addresses a different pharmaceutical or service line altogether.